華蘭生物(002007.SZ):2022年度淨利同比下降17.14% 擬10派3元
格隆匯3月29日丨華蘭生物(002007.SZ)披露2022年年度報吿,報吿期內,公司實現營業收入45.17億元,同比增長1.82%;歸屬於上市公司股東的淨利潤10.76億元,同比下降17.14%;歸屬於上市公司股東的扣除非經常性損益的淨利潤8.94億元,同比下降25.61%;基本每股收益0.5897元,擬向全體股東每10股派發現金紅利3元(含税)。
公司立足血液製品業務,通過增加採漿量、提高血漿綜合利用率、優化產品結構、加大市場急需產品的生產和研發等措施鞏固血液製品行業地位;整合公司研發資源,集中優勢資源開發疫苗新產品,做好四價流感病毒裂解疫苗、四價流感病毒裂解疫苗(兒童劑型)、凍幹人用狂犬病疫苗(Vero細胞)等產品的生產和銷售,做大做強疫苗業務.
開展創新藥和生物類似藥的研發、生產,堅持創新驅動發展戰略,致力於開發用於治療腫瘤、自身免疫性疾病等危及人類生命或健康的重大疾病的藥物,為患者提供安全、有效、可及的藥品,為人類的健康保駕護航;擴大與國內外優勢企業的戰略合作,增強公司的核心競爭力,逐漸形成血液製品、疫苗、創新藥和生物類似藥為核心的大生物產業格局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.